BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

641 related articles for article (PubMed ID: 12886246)

  • 21. Comparative pharmacokinetic studies of three asparaginase preparations.
    Asselin BL; Whitin JC; Coppola DJ; Rupp IP; Sallan SE; Cohen HJ
    J Clin Oncol; 1993 Sep; 11(9):1780-6. PubMed ID: 8355045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma.
    Evans WE; Tsiatis A; Rivera G; Murphy SB; Dahl GV; Denison M; Crom WR; Barker LF; Mauer AM
    Cancer; 1982 Apr; 49(7):1378-83. PubMed ID: 7037164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
    Keating GM
    BioDrugs; 2013 Aug; 27(4):413-8. PubMed ID: 23794007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia.
    Wang B; Hak LJ; Relling MV; Pui CH; Woo MH; Storm MC
    J Immunol Methods; 2000 May; 239(1-2):75-83. PubMed ID: 10821949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
    Salzer WL; Asselin B; Supko JG; Devidas M; Kaiser NA; Plourde P; Winick NJ; Reaman GH; Raetz E; Carroll WL; Hunger SP
    Blood; 2013 Jul; 122(4):507-14. PubMed ID: 23741010
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase.
    Billett AL; Carls A; Gelber RD; Sallan SE
    Cancer; 1992 Jul; 70(1):201-6. PubMed ID: 1606543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia].
    Liu F; Wan Y; Chang L; Guo Y; Yang W; Wang S; Chen X; Liu T; Ruan M; Zhang L; Liu X; Zou Y; Chen Y; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Mar; 52(3):215-7. PubMed ID: 24824393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial.
    Duval M; Suciu S; Ferster A; Rialland X; Nelken B; Lutz P; Benoit Y; Robert A; Manel AM; Vilmer E; Otten J; Philippe N
    Blood; 2002 Apr; 99(8):2734-9. PubMed ID: 11929760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
    Henriksen LT; Harila-Saari A; Ruud E; Abrahamsson J; Pruunsild K; Vaitkeviciene G; Jónsson ÓG; Schmiegelow K; Heyman M; Schrøder H; Albertsen BK;
    Pediatr Blood Cancer; 2015 Mar; 62(3):427-33. PubMed ID: 25418987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.
    Vrooman LM; Kirov II; Dreyer ZE; Kelly M; Hijiya N; Brown P; Drachtman RA; Messinger YH; Ritchey AK; Hale GA; Maloney K; Lu Y; Plourde PV; Silverman LB
    Pediatr Blood Cancer; 2016 Feb; 63(2):228-33. PubMed ID: 26376459
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
    Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Activity of Erwinia-asparaginase after anaphylactic reaction to Peg-asparaginase].
    Viña Romero MM; García Gil S; Nazco Casariego GJ; Merino Alonso J; Gutiérrez Nicolás F
    An Pediatr (Engl Ed); 2019 Mar; 90(3):187-188. PubMed ID: 29705180
    [No Abstract]   [Full Text] [Related]  

  • 33. Outcomes Following Discontinuation of E. coli l-Asparaginase Upon Severe Allergic Reactions in Children With Acute Lymphoblastic Leukemia.
    Yen HJ; Chang WH; Liu HC; Yeh TC; Hung GY; Wu KH; Peng CT; Chang YH; Chang TK; Hsiao CC; Sheen JM; Chao YH; Chang TT; Chiou SS; Lin PC; Wang SC; Lin MT; Ho WL; Chen YC; Liang DC
    Pediatr Blood Cancer; 2016 Apr; 63(4):665-70. PubMed ID: 26703788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia].
    Takahashi H; Koh K; Kato M; Isobe K; Yasui N; Mori M; Akiyama K; Kikuchi A; Hanada R
    Rinsho Ketsueki; 2013 Apr; 54(4):370-7. PubMed ID: 23666219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials.
    Willer A; Gerss J; König T; Franke D; Kühnel HJ; Henze G; von Stackelberg A; Möricke A; Schrappe M; Boos J; Lanvers-Kaminsky C
    Blood; 2011 Nov; 118(22):5774-82. PubMed ID: 21940824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
    Kloos RQH; Pieters R; Jumelet FMV; de Groot-Kruseman HA; van den Bos C; van der Sluis IM
    J Clin Oncol; 2020 Mar; 38(7):715-724. PubMed ID: 31922920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences.
    Burke MJ; Zalewska-Szewczyk B
    Future Oncol; 2022 Mar; 18(10):1285-1299. PubMed ID: 35107320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL).
    Avramis VI; Avramis EV; Hunter W; Long MC
    Anticancer Res; 2009 Jan; 29(1):299-302. PubMed ID: 19331165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia.
    Petersen WC; Clark D; Senn SL; Cash WT; Gillespie SE; McCracken CE; Keller FG; Lew G
    Pediatr Hematol Oncol; 2014 May; 31(4):311-7. PubMed ID: 24498943
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia.
    Mall V; Thomas KB; Sauter S; Niemeyer CM; Sutor AH
    Klin Padiatr; 1999; 211(4):205-10. PubMed ID: 10472551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.